摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-((R)-10-{(S)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-triethylsilanyloxy-methyl}-7-triisopropylsilanyloxy-10H-9-thia-phenanthren-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester | 845440-59-7

中文名称
——
中文别名
——
英文名称
(2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-((R)-10-{(S)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-triethylsilanyloxy-methyl}-7-triisopropylsilanyloxy-10H-9-thia-phenanthren-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester
英文别名
——
(2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-((R)-10-{(S)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-triethylsilanyloxy-methyl}-7-triisopropylsilanyloxy-10H-9-thia-phenanthren-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester化学式
CAS
845440-59-7
化学式
C54H77NO13SSi2
mdl
——
分子量
1036.44
InChiKey
NODGGYYFIHLPLX-SQLDMSABSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    11.36
  • 重原子数:
    71.0
  • 可旋转键数:
    22.0
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    154.59
  • 氢给体数:
    0.0
  • 氢受体数:
    15.0

反应信息

  • 作为反应物:
    描述:
    (2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-((R)-10-{(S)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-triethylsilanyloxy-methyl}-7-triisopropylsilanyloxy-10H-9-thia-phenanthren-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester四丁基氟化铵溶剂黄146 作用下, 以80%的产率得到(2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-((R)-7-hydroxy-10-{(S)-hydroxy-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-methyl}-10H-9-thia-phenanthren-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester
    参考文献:
    名称:
    Estrogen Receptor Ligands. 12. Synthesis of the Major Metabolites of an ERα-Selective, Dihydrobenzoxathiin Antagonist for Osteoporosis
    摘要:
    During the course of drug metabolism studies, a major metabolite of compound 1 was detected in rhesus monkeys and assigned structure 4. The intriguing biotransformation of 1 leading to 4 was confirmed by a 19-step total synthesis starting from resorcinol (11). the key feature of which was the construction of the oxygen bridge utilizing a phenolic oxidation and trapping sequence. In addition.. the synthesis of a related metabolite (5) is described.
    DOI:
    10.1021/ol047741f
  • 作为产物:
    描述:
    methyl 2,3,4-tri-O-acetyl-α,β-D-glucopyranosyluronate trichloroacetimidate 、 (6R)-6-[(S)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-triethylsilyloxymethyl]-3-tri(propan-2-yl)silyloxy-6H-benzo[c]thiochromen-8-ol 在 三氟化硼乙醚 作用下, 以 二氯甲烷 为溶剂, 以70%的产率得到(2S,3S,4S,5R,6S)-3,4,5-Triacetoxy-6-((R)-10-{(S)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-triethylsilanyloxy-methyl}-7-triisopropylsilanyloxy-10H-9-thia-phenanthren-2-yloxy)-tetrahydro-pyran-2-carboxylic acid methyl ester
    参考文献:
    名称:
    Estrogen Receptor Ligands. 12. Synthesis of the Major Metabolites of an ERα-Selective, Dihydrobenzoxathiin Antagonist for Osteoporosis
    摘要:
    During the course of drug metabolism studies, a major metabolite of compound 1 was detected in rhesus monkeys and assigned structure 4. The intriguing biotransformation of 1 leading to 4 was confirmed by a 19-step total synthesis starting from resorcinol (11). the key feature of which was the construction of the oxygen bridge utilizing a phenolic oxidation and trapping sequence. In addition.. the synthesis of a related metabolite (5) is described.
    DOI:
    10.1021/ol047741f
点击查看最新优质反应信息